Topics
Latest
AI
Amazon
Image Credits:Steve Jennings / Getty Images
Apps
Biotech & Health
clime
Image Credits:Steve Jennings / Getty Images
Cloud Computing
Commerce
Crypto
Enterprise
EVs
Fintech
fund-raise
contraption
Gaming
Government & Policy
computer hardware
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
societal
quad
Startups
TikTok
Transportation
Venture
More from TechCrunch
Events
Startup Battlefield
StrictlyVC
Podcasts
video
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
NewLimit , a startup that aims to increase how long people can live a sizable life history by genetically programming their prison cell , has raised a $ 130 million Series B led by Kleiner Perkins .
newfangled investor Nat Friedman , Daniel Gross , and Khosla Ventures also invested , as did returning backers Founders Fund , Dimension Capital , Elad Gil , Garry Tan , Patrick Collison , and others . The fundraise comes two years after the fellowship promote a$40 million Series A.
establish over four years ago by Coinbase CEO Brian Armstrong ( pictured above ) , former GV better half Blake Byers , and stem cellphone prof Jacob Kimmel , NewLimit claims it has made significant progress toward developing treatment that can restore youthful characteristic to aged jail cell .
Kimmel tell TechCrunch the company has discovered three epitome medicines that reprogram liver cell . NewLimit ’s science lab experiments , he said , show this greening can reestablish the prison cell ’ ability to treat fat and inebriant .
The caller measure out its procession by contrasting how cells from a younger individual and an sometime person respond to the centre . An elder liver cell that has gone through NewLimit ’s epigenetic reprogramming behaves more like a jr. cell , Kimmel said .
Promising early results notwithstanding , NewLimit is still a few long time away from set off human trial .
In the meantime , the party wants to go along develop new anti - ageing medicine using an AI model and then testing the most hopeful of these simple machine - generated drugs in its laboratory . “ What the AI model set aside us to do is bunk all those experiments in model and then only follow up on the most promising subset , ” Kimmel said , adding that the data orient from the experimentation are then used to retrain the AI model in a physical process known as “ lab in a eyelet . ”
Join us at TechCrunch Sessions: AI
Exhibit at TechCrunch Sessions: AI
Other noteworthy biotech startups developing drug that aim to increase life-time admit Retro Biosciences , which elevate $ 180 million from OpenAI CEO Sam Altman two years ago and is reportedly raise a$1 billion Series A;and Altos Labs , whichlaunchedwith $ 3 billion in 2022 and is backed by Jeff Bezos .
